This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GFI1 / Zinc finger protein Gfi-1 · IHC design guide
Design Immunohistochemistry for GFI1
Plan chromogenic paraffin IHC for GFI1 and assess nuclear staining (HPA tissue IHC). Start with 0.5–1 μg/mL of the catalog antibody (datasheet A00888-1), and interpret results in light of HPA's uncertain staining reliability (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
GFI1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | General nuclear expression (HPA tissue IHC) | |
| Staining pattern | General nuclear staining across tissues (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A00888-1) | |
| Positive control | Bone marrow+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Marrow/lymphoid RNA group enrichment (HPA tissue IHC: RNA) | |
| Isoform / epitope | No isoforms or processing annotated; epitope impact unknown (UniProt) |
Section 1
Recommended GFI1 IHC & IF Protocols
The catalog antibody protocol uses citrate retrieval (datasheet A00888-1); the published cartilage and knee joint IHC protocol uses enzymatic retrieval (PMC12332208).
| Sample | Paraffin-embedded human mammary cancer tissue; fixative not specified (datasheet A00888-1) |
| Fixation | Image fixative and duration unreported (datasheet A00888-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A00888-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00888-1) |
| Primary antibody | Rabbit anti-GFI1, 1μg/ml (datasheet A00888-1) |
| Primary incubation | Overnight at 4 °C (datasheet A00888-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A00888-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | GFI1-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: High). HPA tissue profile: General nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6 heat retrieval (datasheet A00888-1); consider trypsin–EDTA for cartilage or knee sections (PMC12332208).
Section 2
What Is the Expected GFI1 Staining Pattern?
GFI1 is a nuclear protein with no transmembrane segment; it can colocalize with PIAS3 and RUNX1T1 in nuclear dots (UniProt Q99684). In paraffin-section IHC, look for nuclear staining in hematopoietic cells of bone marrow and in other cell populations scored High by HPA (HPA: tissue IHC). Treat the pattern as provisional: HPA rates its tissue staining Uncertain because antibody staining and RNA expression have low consistency (HPA: reliability Uncertain).
| Clear nuclear staining in bone marrow hematopoietic cells, with limited staining outside nuclei. | This matches GFI1's annotated nuclear location and HPA's High staining in those cells (UniProt Q99684; HPA: High in bone marrow hematopoietic cells). Nuclear dots are plausible, but a dotted pattern is not required for a positive IHC result (UniProt Q99684: colocalization in nuclear dots). |
| Predominantly cytoplasmic, membranous, or extracellular staining with little nuclear signal. | That distribution conflicts with the annotated nuclear location and absence of a transmembrane segment (UniProt Q99684). Consider nonspecific staining or detection artefact before calling it GFI1; HPA's Uncertain tissue-IHC reliability adds reason to verify the pattern (HPA: reliability Uncertain). |
| Strong staining in a cell population expected to show Low staining, such as pancreatic exocrine glandular cells. | This differs from the reported Low pattern for that population (HPA: Low in pancreatic exocrine glandular cells). Check whether the signal is nuclear and survives controls; cross-reactivity or endogenous detection activity is possible, but the HPA rating does not establish the cause (HPA: reliability Uncertain; standard IHC practice). |
| Broad, diffuse color across nuclei and surrounding tissue, without a discernible cell-specific pattern. | Diffuse background cannot establish nuclear GFI1 staining (UniProt Q99684: nucleus). Examine the no-primary control and optimize detection and blocking conditions using standard IHC practice; HPA reports a general nuclear profile but rates its tissue-IHC evidence Uncertain (HPA: tissue IHC profile and reliability). |
| No nuclear signal in bone marrow hematopoietic cells. | This misses a reported High-staining population, so first assess whether the IHC run worked (HPA: High in bone marrow hematopoietic cells; standard IHC practice). Review a concurrently processed positive section, antibody dilution, detection reagents, and the counterstain before interpreting absence of GFI1 (standard IHC practice). |
💡Expected GFI1 appearanceA positive chromogenic IHC result is distinct nuclear staining in bone marrow hematopoietic cells, potentially including nuclear dots; predominantly cytoplasmic or widespread diffuse color is suspect (HPA: High in bone marrow hematopoietic cells; UniProt Q99684: nucleus and nuclear dots).
| Expected compartment | GFI1 is annotated in the nucleus, sometimes colocalizing in nuclear dots, and has no transmembrane segment (UniProt Q99684). Score nuclear signal first; a membrane-dominant pattern needs independent verification (UniProt Q99684; standard IHC practice). |
| Cell population and tissue | HPA scores hematopoietic cells in bone marrow High, while pancreatic exocrine glandular cells and adipocytes are Low (HPA: tissue IHC). Compare like cell populations rather than treating every cell in a section as an equivalent positive control (standard IHC practice). |
| Strength of IHC evidence | HPA calls the tissue pattern Uncertain because staining and RNA expression show low consistency; its listed antibody CAB011197 has IHC status Uncertain (HPA: tissue reliability; HPA: CAB011197 IHC Uncertain). Interpret intensity and unexpected positives cautiously. |
| RNA versus stained cells | HPA reports group-enriched RNA in bone marrow and lymphoid tissue, alongside High protein staining in several listed cell populations outside those groups (HPA: RNA specificity; HPA: tissue IHC). RNA enrichment alone does not resolve whether an individual stained nucleus is specific (standard IHC interpretation). |
| Situation | Likely cause | Next action |
|---|---|---|
| Bone marrow section lacks nuclear staining. | The result conflicts with HPA's High call for hematopoietic cells, but a failed IHC run and true sample variation require different checks (HPA: High in bone marrow hematopoietic cells; standard IHC practice). | Inspect a concurrently stained positive section, then check section quality, primary dilution, retrieval conditions, and detection reagents; use the catalog antibody's IHC-P protocol for its specified settings (standard IHC practice). |
| Color is strongest in cytoplasm or along cell borders. | This conflicts with GFI1's nuclear annotation and lack of a transmembrane segment (UniProt Q99684). Nonspecific binding or detection background is possible (standard IHC practice). | Compare the no-primary control and nuclear counterstain; reassess primary and detection conditions before scoring the signal as GFI1 (standard IHC practice). |
| Many unrelated structures stain diffusely. | A diffuse deposit does not reproduce HPA's general nuclear profile and may reflect assay background (HPA: tissue IHC profile; standard IHC practice). | Check the no-primary control, blocking and washes, then reduce detection background according to the reagents' instructions; score only discernible cellular staining (standard IHC practice). |
| A Low-scored cell population shows intense nuclear staining. | The observation differs from HPA's Low call, while HPA's Uncertain reliability prevents a definitive specificity judgment from that comparison alone (HPA: tissue IHC; HPA: reliability Uncertain). | Confirm cell identity and compare a reported High population in the same run; consider independent antibody or orthogonal evidence before accepting the unexpected positive (standard IHC practice). |
| Two sections give different staining intensity. | HPA reports low consistency between antibody staining and RNA expression, so its tissue scores are an uncertain benchmark; routine IHC processing differences may also affect comparisons (HPA: reliability Uncertain; standard IHC practice). | Compare matched cell populations and controls across runs, and review the recorded retrieval, dilution, detection, and counterstain conditions before assigning a biological difference (standard IHC practice). |
| Can IF/ICC establish the same GFI1 pattern? | HPA provides no main ICC-IF location or cell-line ICC-IF images for GFI1; its tissue-IHC pattern is rated Uncertain (HPA: subcellular record; HPA: reliability Uncertain). | Use the separate IF/ICC guide for that assay. Here, treat nuclear localization as the UniProt expectation and assess the paraffin-section IHC result against its own controls (UniProt Q99684: nucleus; standard IHC practice). |
Experiment evidence
IHC & IF images showing GFI1 staining
A00888-1 · IHCIHC analysis of GFI1 using anti-GFI1 antibody (A00888-1). GFI1 was detected in paraffin-embedded section of human mammary cancer tissue. Hea
A00888-1 · IHCIHC analysis of GFI1 using anti-GFI1 antibody (A00888-1). GFI1 was detected in paraffin-embedded section of human rectal cancer tissue. Heat
A00888-3 · IHCIHC analysis of GFI1 using anti-GFI1 antibody (A00888-3). GFI1 was detected in paraffin-embedded section of human rectal cancer tissue. Heat
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/cerebral+cortex#imid_3184080
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/colon#imid_3184014
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/liver#imid_3184023
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000162676-GFI1/tissue/kidney#imid_3184016
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for GFI1 IHC & IF
🧪Run bone marrow first and expect nuclear staining in hematopoietic cells (HPA: High in bone marrow hematopoietic cells; UniProt Q99684: nucleus). HPA detects GFI1 in all 45 scored tissues, so use no-primary and isotype controls for negative staining; neighboring cells without nuclear signal can provide a background reference, but are not validated negative cells (HPA: detected in all 45 scored tissues; UniProt Q99684: nucleus).
Positive control tissue: Bone marrow (Hematopoietic cells, HPA High)
Negative control tissue: None in HPA: GFI1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for GFI1; derive a cell-line control from the positive tissue's cell type (Hematopoietic cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only section, a host-matched rabbit IgG isotype control, and GFI1 knockout material processed in parallel if available (selected IHC caption: rabbit anti-GFI1 antibody; standard IHC controls). In bone marrow, quench endogenous peroxidase and check for endogenous biotin when using the caption’s avidin–biotin detection system (selected IHC caption: SABC with DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A00888-1 paraffin-section caption does not state the fixative (selected IHC caption: fixative not stated). Heat retrieval in citrate buffer at pH 6 for 20 minutes is a documented starting condition, but the caption does not establish that retrieval is required (selected IHC caption: citrate retrieval). No matched frozen-section or IF/ICC protocol is supplied, so neither can be judged easier; bone marrow requires attention to endogenous peroxidase and, with avidin–biotin detection, endogenous biotin (supplied protocol evidence: IHC caption only; standard IHC practice).
HPA tissue IHC evidence for GFI1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: GFI1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced GFI1 IHC Tips
GFI1 is a nuclear transcription repressor (UniProt Q99684). Interpret chromogenic staining cautiously because tissue IHC shows low consistency with RNA expression (HPA: reliability uncertain).
What retrieval should I try first when nuclear GFI1 staining is weak?
Start with heat-mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet A00888-1). That condition accompanied GFI1 staining in a paraffin section, although the caption does not state the fixative (datasheet A00888-1). If nuclei remain weak, vary heating time on adjacent sections while keeping the antibody concentration and detection steps constant (standard IHC practice). Include a bone marrow section with hematopoietic cells as a candidate positive control, but assess its result cautiously because HPA staining has low consistency with RNA expression (HPA: high in bone marrow hematopoietic cells; reliability uncertain).
How should I troubleshoot weak GFI1 staining when the tissue fixative is unknown?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not report its fixative (datasheet A00888-1). Record the fixative, fixation duration, and processing history for each section before comparing staining intensity (standard IHC practice). Apply citrate pH 6 retrieval for 20 minutes consistently across comparison sections, then change one processing variable at a time (datasheet A00888-1; standard IHC practice). Use an internal positive control when available and compare intact nuclei in similar tissue regions, since fixation and processing differences can confound chromogenic IHC comparisons (standard IHC practice). Do not assign a GFI1-specific fixation effect without direct validation.
How do I assess nuclear GFI1 staining versus cytoplasmic or punctate signal?
Score staining within intact nuclei first: GFI1 is annotated as nuclear and can colocalize with PIAS3 and RUNX1T1 in nuclear dots (UniProt Q99684). A nuclear punctate pattern can therefore be plausible, but morphology alone cannot establish that individual dots contain GFI1 (UniProt Q99684; standard IHC practice). Review the hematoxylin counterstain alongside DAB to define nuclear boundaries, especially in crowded hematopoietic cells (standard IHC practice; HPA: high in bone marrow hematopoietic cells). Treat predominantly cytoplasmic or diffuse extracellular color as a troubleshooting signal; compare a no-primary control and an independent antibody before interpreting it as GFI1 (UniProt Q99684 nucleus; standard IHC practice).
Could epitope placement explain different GFI1 staining between antibodies?
The supplied record lists one 422-amino-acid chain and 0 annotated isoforms; it does not identify the catalog antibody's epitope (UniProt Q99684; datasheet A00888-1). GFI1 has no annotated transmembrane segment, so a membrane-facing epitope explanation does not follow from its topology (UniProt Q99684 topology). Phosphoserines at positions 20 and 56 are annotated, but their effect on this antibody's staining is unknown (UniProt Q99684 modified residues). If two antibodies disagree, check each immunogen or epitope record, compare nuclear staining in matched sections, and verify specificity with an orthogonal control before assigning an isoform or modification effect (standard IHC practice).
How can IF help resolve ambiguous chromogenic GFI1 staining?
Use IF as a complementary localization check for the IHC result, with a validated marker of the expected hematopoietic cell population in bone marrow (HPA: high in bone marrow hematopoietic cells; standard IF practice). Choose fluorophores in channels with low measured tissue autofluorescence, and include single-stain and no-primary controls for multiplex interpretation (standard IF practice). Because GFI1 is nuclear and has no transmembrane segment, permeabilize sufficiently for antibody access to nuclear epitopes; optimize that step for the IF antibody and specimen (UniProt Q99684 nucleus and topology; standard IF practice). Concordant nuclear signal can support interpretation, but IF conditions and specificity require their own validation (standard IF practice).
What should I check when DAB appears outside plausible GFI1-positive nuclei?
First compare the section with a no-primary control to identify detection-system or tissue-associated color (standard IHC practice). The selected protocol uses a biotinylated secondary, streptavidin–biotin complex, and DAB, so assess endogenous biotin and peroxidase contributions in the same tissue (datasheet A00888-1; standard IHC practice). A peroxidase block and appropriate blocking controls are general chromogenic IHC steps; the caption specifically reports 10% goat serum blocking (standard IHC practice; datasheet A00888-1). Recheck wash stringency and primary concentration against the caption's 1 µg/ml condition, then prioritize signal confined to intact nuclei (datasheet A00888-1; UniProt Q99684 nucleus).
How should I quantify GFI1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define a nuclear scoring rule before examining groups, then report the percentage of positive cells or an H-score from nuclear intensity and positive-cell fraction (UniProt Q99684 nucleus; standard IHC practice). For sparse populations, positive nuclei per mm² can supplement those measures (standard IHC practice). Normalize to the number of evaluable nuclei in the relevant cell population, or to analyzed tissue area for density, using the same region-selection rules across sections (standard IHC practice). Record processing and staining batches, and interpret between-tissue differences cautiously because HPA reports uncertain reliability from low agreement between antibody staining and RNA expression (HPA: reliability uncertain).
When should I question an apparent GFI1-positive cell?
Prioritize staining in an intact nucleus within an identifiable cell, consistent with GFI1's nuclear annotation (UniProt Q99684 nucleus). Bone marrow hematopoietic cells are a candidate positive population, but HPA calls its tissue staining reliability uncertain because antibody staining and RNA expression have low consistency (HPA: high in bone marrow hematopoietic cells; reliability uncertain). Question color limited to section edges, necrotic regions, or cells with poorly preserved nuclei, and inspect matched controls for endogenous enzyme or biotin signal (standard IHC practice; datasheet A00888-1 biotin-based DAB detection). Confirm consequential findings with an independent antibody or orthogonal expression evidence before assigning cell identity from DAB alone (standard IHC practice).
Boster reagents
Best GFI1 / Zinc finger protein Gfi-1 IHC Antibodies
Two anti-GFI1 antibodies have real IHC images from human paraffin sections: mammary cancer and rectal cancer tissue (catalog IHC captions). Both list human, mouse and rat reactivity (catalog).
Real IHC data
Anti-GFI1 Antibody
Cat # A00888-1
Real IHC data
Anti-GFI1 Antibody ®
Cat # A00888-3
A00888-1 lists IHC for human, mouse and rat and shows GFI1 staining in human mammary cancer paraffin sections (catalog applications, reactivity and IHC caption). A00888-3 lists IHC for human tissue and shows GFI1 staining in human rectal cancer paraffin sections (catalog dilution entry and IHC caption).
Which to pick: For tissue IHC, choose A00888-1 for the documented citrate pH 6 retrieval or A00888-3 for the documented EDTA pH 8 retrieval; both captions describe paraffin sections and leave the fixative unreported (catalog IHC captions). Neither SKU lists IF/ICC or provides an IF figure, so neither has documented IF/ICC support here (catalog applications and image records). For cross-species work, A00888-1 is the clearer IHC starting point because it is polyclonal and lists human, mouse and rat reactivity, while A00888-3 specifies human for its IHC dilution; the supplied IHC images for both show human tissue only (catalog dilution entries and IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q99684 (GFI1_HUMAN, Zinc finger protein Gfi-1).
- Human Protein Atlas. GFI1 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. GFI1 subcellular location (ICC-IF): Highest expression in THP-1: 231.3 nTPM.
- Human Protein Atlas. GFI1 antibody validation summary (1 antibodies).
- Growth Factor Independence-1 (Gfi1) Is Required for Pancreatic Acinar Unit Formation and Centroacinar Cell Differentiation. Cellular and molecular gastroenterology and hepatology 2015 — PMC5301134.
- GFI1 promotes the proliferation and migration of esophageal squamous cell carcinoma cells through the inhibition of SOCS1 expression. International journal of molecular medicine 2021 — PMC8416140.
- SAM pointed domain ETS factor (SPDEF) regulates terminal differentiation and maturation of intestinal goblet cells. Experimental cell research 2010 — PMC3004755.
- Growth factor independence 1 ameliorates osteoarthritis by inhibiting chondrocyte ferroptosis via inactivation of MAPK signaling pathway. Journal of orthopaedic translation 2025 — PMC12332208.
- PubMed PMID:9051000 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:8754800 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for GFI1 (Zinc finger protein Gfi-1). Expected localisation General nuclear expression (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A00888-1). Validated IHC antibody: A00888-1 at 1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bone marrow (Hematopoietic cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human mammary cancer tissue; fixative not specified (datasheet A00888-1); 2. Fixation: Image fixative and duration unreported (datasheet A00888-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A00888-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00888-1); 8. Primary antibody: Rabbit anti-GFI1, 1μg/ml (datasheet A00888-1); 9. Primary incubation: Overnight at 4 °C (datasheet A00888-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: No isoforms or processing annotated; epitope impact unknown (UniProt); Regulation: Marrow/lymphoid RNA group enrichment (HPA tissue IHC: RNA). Evidence: UniProt Q99684, HPA tissue IHC · Uncertain, HPA cell-line RNA · Highest expression in THP-1: 231.3 nTPM, Datasheet A00888-1, PMC12332208. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/GFI1/immunohistochemistry-ihc-guide.